Jessica Newcomb - 02 Nov 2026 Form 4 Insider Report for Tango Therapeutics, Inc. (TNGX)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
04 Nov 2026, 19:32:12 UTC
Prior SEC filing
24 Sep 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Julie Fogarty, as attorney-in-fact
Filing notes and source

Key filing fact

Jessica Newcomb filed Form 4 for Tango Therapeutics, Inc. (TNGX) on 04 Nov 2026.

Key facts

  • This page summarizes Jessica Newcomb's Form 4 filing for Tango Therapeutics, Inc. (TNGX).
  • 2 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 04 Nov 2026, 19:32.

Change

  • Previous filing in this sequence was filed on 24 Sep 2026.
  • Current net transaction value: -$157,661.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002130408 Primary reporting owner

Newcomb Jessica

Relationship
Principal Accounting Officer
Address
C/O TANGO THERAPEUTICS, INC., 201 BROOKLINE AVE., SUITE 901, BOSTON
Signature
/s/ Julie Fogarty, as attorney-in-fact
Signature date
04 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TNGX transaction

Common Stock

Sale

Transaction value
-$124,107
Shares
-5,571
Change %
-9.4%
Price
$22.28
Shares after
53,550
Date
02 Nov 2026
Ownership
Direct
Footnotes
F1, F2, F3
TNGX transaction

Common Stock

Sale

Transaction value
-$33,553
Shares
-1,460
Change %
-2.7%
Price
$22.98
Shares after
52,090
Date
02 Nov 2026
Ownership
Direct
Footnotes
F1, F3, F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on June 23, 2026.

Footnote F2

Represents the weighted average sales price per share. The shares sold at prices ranging from $21.815 to $22.8149 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Footnote F3

The amount reported in Column 2 includes 43,666 unvested restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.

Footnote F4

Represents the weighted average sales price per share. The shares sold at prices ranging from $22.82 to $23.8199 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .